InMed Pharmaceuticals is on the rise, and it looks like people are taking notice:
From the Oracle Dispatch (Excerpt and Link below):
INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF) is an interesting player in the MMJ space that we have covered on a few occasions. We generally think IMLFF is a promising story despite the fact that it has had its share of promotional action. One of the reasons for that sense is the company’s habit of innovation and focus on intellectual property. That concept was on display again this week, so we thought it was a good time for an update.
Specifically, the company just announced the filing of a provisional patent application pertaining to its proprietary biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature. According to the release, “The patent application, once converted into an international Patent Cooperation Treaty (PCT) application and pursued in key jurisdictions throughout the world, will provide significant commercial protection for InMed’s E. coli-based expression system to manufacture any of the 90+ cannabinoid compounds that may have a medical impact on important human diseases.”
INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF) casts itself as a biopharmaceutical company specializing in developing cannabis-based therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.
IMLFF is utilizing its proprietary Intelligent Cannabinoid Drug Design Platform to identify new bioactive compounds within the cannabis plant that interact with certain gene targets responsible for specific diseases.
The big picture is that this is a pre-clinical stage biopharmaceutical company specializing in the research, development and commercialization of cannabinoid-based therapies to treat human diseases with high unmet medical needs. The Company has three core assets: a proprietary Bioinformatics assessment tool to match individual (or combination of) cannabinoids against disease targets; a proprietary Biosynthesis cannabinoid manufacturing system to economically produce all 90+ cannabinoids at pharmaceutical-grade (>99.5% purity); and drug development program enabled by the two aforementioned tools. Leaders in the pipeline include a treatment for the symptoms and, potentially, the underlying disease in Epidermolysis Bullosa, a rare, devastating genetic skin disorder; and, a once-a-day eyedrops formulation of cannabinoids to treat Glaucoma, one of the leading causes of blindness in the developed world.
READ THE FULL ARTICLE AT ORACLEDISPATCH.COM
Read More
INMED PHARMACEUTICALS (OTC:IMLFF) Pops on Biosynthesis IP Move
